Table 1.

Clinical features, disease state, response in the clinic and in vitro of patient-obtained leukemia treated with pancratistatin.

Patient #	Age	Clinical Diagnosis	% Blasts	Clinical Response	Exposure	% Apoptosis
1	60	AML - M3	85%	censored	24 h	64.9 ± 4.2
2	81	AML-M2	20%	NR	24 h	33.5 ± 7.7
3	53	AMoL-M5a	96%	CR	24 h	46.5 ± 7.9
4	73	CML	9%	censored	24 h	63.9 ± 2.2
5	23	AML-M5a	70%	NR	24 h	30.6 ± 1.6
6	66	ALL-L3	34%	NR	48 h	61.8 ± 9.8
7	62	CMML-M4	32%	NR	48 h	17.7 ± 2.7
8	74	AML-M2	60%	NR	48 h	48.6 ± 6.7
9	45	AML	84%	censored	48 h	63.9 ± 4.2
10	57	AML-M3	43%	PR	48 h	70.8 ± 5.9
11	68	AML-M2	n/a	CR	48 h	46.8 ± 12.2
12	80	Mantel cell lymphoma	0%	censored	48 h	35.2 ± 6.6
13	47	AML	44%	censored	48 h	37.3 ± 7.7
14	71	AML-M0, relapsed	52%	relapsed	48 h	45.3 ± 11.3
15	65	AML-MDS, relapsed	48%	CR	48 h	37.3 ± 8.5